<DOC>
	<DOCNO>NCT00344981</DOCNO>
	<brief_summary>Study Hypothesis Evaluation durability combination Tenofovir Hydroxyurea maintain viral suppression 50 copies/ml volunteer achieve viral suppression standard HAART regimen .</brief_summary>
	<brief_title>Safety Durability ofTenofovir Cell Cycle Agent Viral Suppression</brief_title>
	<detailed_description>This 48 week open-label , randomize study compare safety durability highly active de-intensified therapy ( Tenofovir/Hydroxyurea ) simplify standard care therapy ( Tenofovir plus 3TC Emtriva plus Sustiva Nevirapine ) maintain durable viral suppression . Up 20 subject chronic HIV-1 infection , suppress highly active antiretroviral therapy , without evidence viral resistance enrol study . Their present HAART therapy stop . Half 20 volunteer randomize Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm subject Hydroxyurea add current screen regimen 4 week prior de-intensifying Hydroxyurea Tenofovir . The half randomized Sustiva 600 mg qd Nevirapine 200 mg twice day ) ; Tenofovir 300 mg qd , 3TC 300 mg qd Emtriva 200 mg day . Volunteers continue regimen 48 week . Patients monitor immunological virological parameter well incidence toxicity side effect study . If patient 's viral load reach &gt; 400 copies/ml 3 consecutive measurement 6 week period , terminate study start back HAART .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Diagnosis HIV infection base western blot test , ELISA , HIV viral load 2 . Age great equal 18 year 3 . CD4 count great equal 200c/ml . 4 . On standard HAART regimen 2 3 nucleoside reverse transcriptase inhibitor either protease inhibitor nonnucleoside reverse transcriptase inhibitor 3 nucleoside reverse transcriptase inhibitor ( 23NRTI 's + PI 23NRTI 's +NNRTI 3NRTI 's ) . 5 . On stable , continuous HAART regimen great equal 3 month , 6 . Viral load less equal 400c/ml measurement precede 6 month least 2 measurement ( screen viral load include need ) 7 . Viral load less equal 50c/ml screen 8 . Subject able comply study protocol 9 . Signed informed consent 10 . No history antiretroviral failure suspect result antiretroviral resistance . 1 . Serious HIV relate non HIV relate carcinoma require chemotherapy 2 . Recent serious opportunistic infection , progressive multifocal leukoencephalopathy , CMV disease , cryptococcus meningitis , cerebral toxoplasmosis , exclude infection successful treatment may judge place risk antiretroviral therapy de intensify . 3 . Known suspected intolerance hypersensitivity Hydroxyurea 4 . Grade 3 high neutropenia ( use ACTG grade table ) 5 . Grade 2 high thrombocytopenia ( use ACTG grade table ) 6 . Grade 2 high LFT abnormality ( use ACTG grade table ) 7 . History pancreatitis , risk factor associate pancreatitis ( two drink contain alcohol/day , triglyceride level great 400 , pancreatic enzyme great 1.5x normal ) 8 . Renal insufficiency ( Estimated Creatinine clearance &lt; 60ml/min . ) 9 . Chronic diarrhea 10 . Pregnancy breastfeed 11 . Unwillingness use effective barrier contraception abstinence 12 . The use systemic corticosteroid , systemic immunosuppressive medication ; use cholestyramine ; use probenecid inhibitor renal tubular secretion 13 . Genotypic phenotypic test document major resistance antiretroviral agent 14 . Active substance mental health concern judge place significant limitation medication adherence .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Cell Cycle Agents</keyword>
</DOC>